Clinical trials of anti-amyloid and anti-tau intervention for AD have been conducted but meaningfully effective drugs are still not available (Congdon and Sigurdsson, 2018; Huang et al., 2020), and their causal role is under question (Kametani and Hasegawa, 2018; Morris et al., 2018; Thomas et al., 2020; Sturchio et al., 2021). Here, MAPT is linked to Alzheimer disease.